Data compiled by Redley Lamar · ChainSifter Intelligence
10Suppliers
1Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Greenwich LifeSciences, Inc. (GLSI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
4High confidence
0.768Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Greenwich LifeSciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
HJF
HJF
90%
We currently are dependent on a license from HJF for technologies relating to our product candidate.
THIRD-PARTY-CONTRACT-MANUFACTURERS
THIRD-PARTY-CONTRACT-MANUFACTURERS
90%
The Company currently depends on third-party contract manufacturers for all required raw materials, active pharmaceutical ingredients, and finished product candidate for the Company’s clinical trials.
duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
Reciprocal relationship from AZN graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from AZN graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from AZN grap…
Reciprocal relationship from GILD graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from GILD g…
duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
Reciprocal relationship from JNJ graph: Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adve…
Reciprocal relationship from MRK graph: Reciprocal relationship from GLSI graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GLSI graph: duct candidate and the average exposu…
duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may only be detected once the product is admin…
Greenwich LifeSciences, Inc. Customers
Ticker
Name
Confidence
Evidence
AEGIS-CAPITAL-CORP
AEGIS-CAPITAL-CORP
62%
. F- 11 Table of Contents GREENWICH LIFESCIENCES, INC. NOTES TO FINANCIAL STATEMENTS Warrants Prior to the IPO, there were no outstanding warrants to purchase shares of common stock accounted for as …
Greenwich LifeSciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
GLSI-DEBT-9804
Warrants outstanding: 8012684
90%
xbrl warrant detail from xbrl 2025-09-30.
Greenwich LifeSciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Greenwich LifeSciences, Inc..
Greenwich LifeSciences, Inc. Ownership
Holder
Name
Confidence
Evidence
GLSI-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 64 tracked holders.
Greenwich LifeSciences, Inc. Extended Supply Chain Network
